诺华制药2023年第一季度业绩超出预期,净销售额同比增长15%至132亿美元,核心营业利润达55.8亿美元,同比增长27%。公司上调了全年净销售额和核心营业利润增长目标,主要得益于Entresto、Cosentyx等畅销药的强劲表现以及Kisqali、Kesimpta和Leqvio等新产品的市场需求增长。尽管面临仿制药竞争压力,诺华制药仍通过加速创新疗法布局和加大在美国的投资来应对挑战,并对未来...
Source Link诺华制药2023年第一季度业绩超出预期,净销售额同比增长15%至132亿美元,核心营业利润达55.8亿美元,同比增长27%。公司上调了全年净销售额和核心营业利润增长目标,主要得益于Entresto、Cosentyx等畅销药的强劲表现以及Kisqali、Kesimpta和Leqvio等新产品的市场需求增长。尽管面临仿制药竞争压力,诺华制药仍通过加速创新疗法布局和加大在美国的投资来应对挑战,并对未来...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.